Back to today’s briefing

Story perspectives

Hims & Hers Launches Multi-Cancer Test Amid Stock Struggles

2/6/2026

34 6 Full Breakdown

Summary

Story summary

Hims & Hers Health, Inc. launched a Galleri-powered Multi-Cancer Test to screen for over 50 cancer types.
Hims & Hers Health, Inc. stock has traded below moving averages and fallen 38.2% over the past year.
The test aims to detect signals before symptoms arise, potentially improving treatment outcomes.
Hims & Hers Health, Inc. reported a 49.2% revenue increase in Q3 2025.

History

Historical Context

In June 2021, Grail launched the Galleri test, a multi-cancer early detection tool, following its founding in 2015 and acquisition by Illumina in 2021. Despite its potential, early trials faced criticism for poor results. As cancer remains a leading cause of death, advancements like Galleri underscore the urgent need for innovative screening solutions in healthcare, especially amid market volatility affecting health tech firms.

1 of 2

Story summary

Hims & Hers Health, Inc. launched a Galleri-powered Multi-Cancer Test to screen for over 50 cancer types.
Hims & Hers Health, Inc. stock has traded below moving averages and fallen 38.2% over the past year.
The test aims to detect signals before symptoms arise, potentially improving treatment outcomes.
Hims & Hers Health, Inc. reported a 49.2% revenue increase in Q3 2025.

1 / 2